Vigonvita shares rocketed 185% on HK market debut.
The biopharmaceutical company offered 17.6 million H-shares in the global offering.
The Hong Kong public offer was 6,238.42 times oversubscribed, with a final allocation of 1.76 million shares, or 10% of the total offering.
The international offering was 16.87 times subscribed, with a final allocation of 15.8 million shares, or 90% of the total.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.